Crescent Biopharma (CBIO) EPS (Weighted Average and Diluted) (2013 - 2024)
Crescent Biopharma (CBIO) reported EPS (Weighted Average and Diluted) of -$0.11 for Q4 2024, up 21.43% year-over-year from -$0.09 in Q1 2024, and up 26.67% quarter-over-quarter from -$0.15 in Q3 2024.
Crescent Biopharma (CBIO) EPS (Weighted Average and Diluted) (2013 - 2024) Analysis & Trends
Crescent Biopharma (CBIO) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.11 in Q4 2024.
- EPS (Weighted Average and Diluted) for Q4 2024 came in at -$0.11, up 21.43% year-over-year; the trailing twelve-month figure through Dec 2024 was -$0.46 (up 20.69% YoY), and the FY2024 annual result was -$0.59, down 1.72% from the prior year.
- EPS (Weighted Average and Diluted) rose to -$0.11 in Q4 2024 per CBIO's latest filing, from -$0.15 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.04 in Q1 2024 and troughed at -$0.34 in Q4 2020.
- A 5-year average of -$0.21 and a median of -$0.17 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 76.47% in 2024 and fell as far as 23.08% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.34 in 2020, then climbed by 3.05% to -$0.33 in 2021, then surged by 42.42% to -$0.19 in 2022, then climbed by 26.32% to -$0.14 in 2023, then gained by 21.43% to -$0.11 in 2024.
- Business Quant data shows CBIO's EPS (Weighted Average and Diluted) at -$0.11 in Q4 2024, -$0.15 in Q3 2024, and -$0.16 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -0.11 |
| Sep 30, 2024 | -0.15 |
| Jun 30, 2024 | -0.16 |
| Mar 31, 2024 | -0.04 |
| Dec 31, 2023 | -0.14 |
| Sep 30, 2023 | -0.14 |
| Jun 30, 2023 | -0.13 |
| Mar 31, 2023 | -0.17 |
| Dec 31, 2022 | -0.19 |
| Sep 30, 2022 | -0.16 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.28 |
| Dec 31, 2021 | -0.33 |
| Sep 30, 2021 | -0.34 |
| Jun 30, 2021 | -0.28 |
| Mar 31, 2021 | -0.28 |
| Dec 31, 2020 | -0.34 |
| Dec 31, 2019 | -0.34 |
| Jun 30, 2016 | -0.41 |
| Dec 31, 2015 | -0.47 |